Psoriasis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Luke Rusowicz-Orazem (talk | contribs)
No edit summary
Skazmi (talk | contribs)
No edit summary
Line 4: Line 4:
==Overview==
==Overview==
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Prevalence===
===Prevalence<ref name="pmid15708928">{{cite journal |vauthors=Langley RG, Krueger GG, Griffiths CE |title=Psoriasis: epidemiology, clinical features, and quality of life |journal=Ann. Rheum. Dis. |volume=64 Suppl 2 |issue= |pages=ii18–23; discussion ii24–5 |year=2005 |pmid=15708928 |pmc=1766861 |doi=10.1136/ard.2004.033217 |url=}}</ref>===
The [[prevalence]] of psoriasis in Western populations is estimated to be around 2-3%.
* Worldwide, the prevalence of psoriasis ranges from a low of 500 per 100,000 persons to a high of 4600 per 100,000 persons.
* The prevalence of psoriasis in the United States is 2000 per 100,000 persons.
 
=== Incidence<ref name="pmid23014338">{{cite journal |vauthors=Parisi R, Symmons DP, Griffiths CE, Ashcroft DM |title=Global epidemiology of psoriasis: a systematic review of incidence and prevalence |journal=J. Invest. Dermatol. |volume=133 |issue=2 |pages=377–85 |year=2013 |pmid=23014338 |doi=10.1038/jid.2012.339 |url=}}</ref> ===
* Worldwide, the incidence of psoriasis ranges from a low of 78.9 per 100,000 persons (United States) to 230 per 100,000 persons (Italy).


===Age===
===Age===
Onset before age 40 usually indicates a greater genetic susceptibility and a more severe or recurrent course of psoriasis.
* The mean age for development of psoriasis can be divided into two peaks with the mean of first peak between 15 years to 25 years of age and mean of second peak occuring at 55 years to 60 years of age.<ref name="urlPsoriasis: epidemiology, clinical features, and quality of life | Annals of the Rheumatic Diseases">{{cite web |url=http://ard.bmj.com/content/64/suppl_2/ii18 |title=Psoriasis: epidemiology, clinical features, and quality of life &#124; Annals of the Rheumatic Diseases |format= |work= |accessdate=}}</ref>
 
=== Ethnicity ===
* Psoriasis tends to affect Caucasians more than other races with a prevalence of 2500 per 100,000 Caucasian persons in the United states which is higher than other ethnic populations in the country.<ref name="pmid150837802">{{cite journal |vauthors=Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T |title=Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction |journal=J. Investig. Dermatol. Symp. Proc. |volume=9 |issue=2 |pages=136–9 |year=2004 |pmid=15083780 |doi=10.1046/j.1087-0024.2003.09102.x |url=}}</ref>


===Gender===
===Gender===
 
* There is no gender predilection for psoriasis, although women are more severely affected once they develop the disease.<ref name="urlPsoriasis - ScienceDirect">{{cite web |url=http://www.sciencedirect.com/science/article/pii/S0140673603129546?via%3Dihub |title=Psoriasis - ScienceDirect |format= |work= |accessdate=}}</ref>
Psoriasis affects both [[sex]]es equally and can occur at any [[ageing|age]], although it most commonly appears for the first time between the ages of 15 and 25 years.  


===Developed Countries===
===Developed Countries===
A [[statistical survey|survey]] [http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf] conducted by the National Psoriasis Foundation (a US based psoriasis education and advocacy group, which is partly funded by [[pharmaceutical company|pharmaceutical companies]]) found a prevalence of 2.1% among adult Americans. The study also found that 35% of people with psoriasis could be classified as having moderate to severe psoriasis.
* Psoriasis tends to affect Northern European and South East Asian countries.<ref name="pmid23374051">{{cite journal |vauthors=Danielsen K, Olsen AO, Wilsgaard T, Furberg AS |title=Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort |journal=Br. J. Dermatol. |volume=168 |issue=6 |pages=1303–10 |year=2013 |pmid=23374051 |doi=10.1111/bjd.12230 |url=}}</ref>


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Primary care]]
[[Category:Primary care]]

Revision as of 15:18, 14 June 2017

Psoriasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Psoriasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X-ray

Ultrasound

CT scan

MRI

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Psoriasis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Psoriasis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Psoriasis epidemiology and demographics

CDC on Psoriasis epidemiology and demographics

Psoriasis epidemiology and demographics in the news

Blogs on Psoriasis epidemiology and demographics

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Psoriasis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Epidemiology and Demographics

Prevalence[1]

  • Worldwide, the prevalence of psoriasis ranges from a low of 500 per 100,000 persons to a high of 4600 per 100,000 persons.
  • The prevalence of psoriasis in the United States is 2000 per 100,000 persons.

Incidence[2]

  • Worldwide, the incidence of psoriasis ranges from a low of 78.9 per 100,000 persons (United States) to 230 per 100,000 persons (Italy).

Age

  • The mean age for development of psoriasis can be divided into two peaks with the mean of first peak between 15 years to 25 years of age and mean of second peak occuring at 55 years to 60 years of age.[3]

Ethnicity

  • Psoriasis tends to affect Caucasians more than other races with a prevalence of 2500 per 100,000 Caucasian persons in the United states which is higher than other ethnic populations in the country.[4]

Gender

  • There is no gender predilection for psoriasis, although women are more severely affected once they develop the disease.[5]

Developed Countries

  • Psoriasis tends to affect Northern European and South East Asian countries.[6]

References

  1. Langley RG, Krueger GG, Griffiths CE (2005). "Psoriasis: epidemiology, clinical features, and quality of life". Ann. Rheum. Dis. 64 Suppl 2: ii18–23, discussion ii24–5. doi:10.1136/ard.2004.033217. PMC 1766861. PMID 15708928.
  2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013). "Global epidemiology of psoriasis: a systematic review of incidence and prevalence". J. Invest. Dermatol. 133 (2): 377–85. doi:10.1038/jid.2012.339. PMID 23014338.
  3. "Psoriasis: epidemiology, clinical features, and quality of life | Annals of the Rheumatic Diseases".
  4. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004). "Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction". J. Investig. Dermatol. Symp. Proc. 9 (2): 136–9. doi:10.1046/j.1087-0024.2003.09102.x. PMID 15083780.
  5. "Psoriasis - ScienceDirect".
  6. Danielsen K, Olsen AO, Wilsgaard T, Furberg AS (2013). "Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort". Br. J. Dermatol. 168 (6): 1303–10. doi:10.1111/bjd.12230. PMID 23374051.

Template:WH Template:WS